CNine Bioscolutions, a US-based biomedical spinout from University of Alabama at Birmingham (UAB), has secured $2m in a seed round backed by assorted angel investors, according to the Birmingham Business Journal. CNine is developing a test that can determine whether a patient’s meningitis is caused by bacterial or viral infections. Bacterial meningitis is generally much more serious than viral meningitis and requires immediate intervention. Current tests produce 10% to 30% false positives and lab tests often require hospital visits, making…